A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia
Latest Information Update: 19 May 2015
Price :
$35 *
At a glance
- Drugs Apabetalone (Primary) ; Atorvastatin; Rosuvastatin
- Indications Coronary artery disease; Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Resverlogix Corporation
- 28 Jun 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Jun 2013 New trial record